The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Impact of first-line cisplatin versus non-cisplatin based chemotherapy on progression-free survival in patients with advanced urothelial carcinoma previously treated with perioperative cisplatin based chemotherapy.
 
Jennifer A Locke
No Relationships to Disclose
 
Gregory Russell Pond
No Relationships to Disclose
 
Guru Sonpavde
No Relationships to Disclose
 
Andrea Necchi
No Relationships to Disclose
 
Patrizia Giannatempo
No Relationships to Disclose
 
Ravi Kumar Paluri
No Relationships to Disclose
 
Guenter Niegisch
No Relationships to Disclose
 
Peter Albers
Honoraria - Dendreon; Hexal; Janssen Oncology; Myriad Genetics; Sandoz; Sanofi
Consulting or Advisory Role - Myriad Genetics; Sanofi
 
Carlo Buonerba
No Relationships to Disclose
 
Giuseppe di Lorenzo
No Relationships to Disclose
 
Ulka N. Vaishampayan
Honoraria - Astellas Pharma; Bayer; Janssen; Novartis; Pfizer
Consulting or Advisory Role - Astellas Pharma; Novartis; Pfizer
Speakers' Bureau - Astellas Pharma; Bayer; Janssen; Novartis; Pfizer
Research Funding - Astellas Pharma; Exelixis; Novartis
 
Scott A. North
No Relationships to Disclose
 
Neeraj Agarwal
Consulting or Advisory Role - Dendreon
Research Funding - amgen (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); GlaxoSmithKline (Inst); ImClone Systems (Inst); Medivation (Inst); Novartis (Inst); Pfizer (Inst); Takeda (Inst)
Other Relationship - Exelixis; Medivation; Takeda
 
Syed A. Hussain
No Relationships to Disclose
 
Bernhard J. Eigl
No Relationships to Disclose